You're on a GLP-1 medication like Ozempic or Mounjaro, and you're seeing results. The weight is coming off. Your blood sugar is stable. But emerging research from 2025 and 2026 suggests you might be overlooking something critical: your bone health. Studies now show that semaglutide and tirzepatide can accelerate bone mineral density loss, especially if you're using them primarily for weight loss without diabetes. Here's what the science says - and what you can do about it.

What the latest studies found about bone density and GLP-1 medications

Two studies presented in 2026 directly examined how GLP-1 medications affect your skeleton. The first, led by Starup-Linde and colleagues, looked at people already at increased risk of fractures. The results were clear: both semaglutide and tirzepatide were linked to significant bone density loss at the hip. The second study, MON-817, compared bone density changes in obese patients with and without diabetes. Researchers are still investigating why, but hip bone mineral density loss was significantly higher in those without diabetes. That's a finding that raises real questions for the millions using these drugs primarily for weight loss.

What about muscle loss?

Bone doesn't exist in isolation. Your muscles pull on your bones during movement, and that mechanical loading helps maintain bone density. The SURMOUNT-1 DXA substudy, published by Look and colleagues in 2025, showed that tirzepatide reduced total lean mass by 10.9% over 72 weeks. That's a lot of muscle. When you lose muscle that quickly, your bones lose some of the stimulus they need to stay strong. This is one reason why muscle loss on Ozempic or Wegovy isn't just about strength or appearance - it's directly tied to your skeletal health.

Why rapid weight loss threatens your bones

Rapid weight loss, regardless of how you achieve it, can reduce both lean mass and bone mineral density. But GLP-1 medications may compound this risk because they suppress appetite so effectively. Many people struggle to consume enough bone-supporting nutrients. Calcium, vitamin D, and protein are essential for maintaining bone structure, yet reduced food intake often means these nutrients fall short. The research is ongoing, but initial results indicate that fracture risk may be highest in the first year of treatment, when weight loss is most rapid. After that, bone density may stabilise - but only if you address the nutritional gaps.

Three nutrients that protect your bones

You can't reverse bone loss overnight, but you can slow it significantly by prioritising these three nutrients:

  • Calcium - Your body needs calcium to build and maintain bone. The National Institutes of Health recommends 1,000-1,200 mg daily for most adults. On a reduced-calorie diet, meeting this through food alone can be challenging. Good sources include dairy, fortified plant milks, leafy greens, and almonds. If you're falling short, a supplement can help.
  • Vitamin D - Vitamin D helps your body absorb calcium. Without enough, even a high-calcium diet won't fully protect your bones. Aim for 600-800 IU daily, though some research suggests higher doses may be beneficial during rapid weight loss. Sunlight, fatty fish, and fortified foods are natural sources. Many people on GLP-1 medications find they need supplementation.
  • Protein - Protein provides the building blocks for muscle and bone collagen. The recommended intake during weight loss is higher than standard guidelines - around 1.2 to 1.5 grams per kilogram of body weight. That's 90-110 grams daily for a 75 kg person. Protein intake on Wegovy or Mounjaro often falls short because appetite is so suppressed. Prioritise lean meats, eggs, dairy, legumes, and protein shakes.

These aren't just nice-to-haves. They're the difference between losing weight and losing bone along with it.

What else you can do to protect your skeleton

Beyond nutrition, resistance exercise is your strongest weapon against bone loss. Weight-bearing activities like walking, jogging, and stair climbing help maintain bone density. But resistance training - lifting weights, using resistance bands, or bodyweight exercises like squats and lunges - provides the direct mechanical loading your bones need. Aim for at least two sessions per week. If you're new to strength training, start with bodyweight exercises and gradually add weight. Your bones adapt slowly, so consistency matters more than intensity.

Other nutrients that support bone and overall health on GLP-1

Calcium, vitamin D, and protein are the headliners, but they don't work alone. Magnesium helps activate vitamin D and supports bone structure. Early findings suggest magnesium deficiency on semaglutide may be more common than people realise, because reduced food intake means less magnesium from sources like nuts, seeds, and whole grains. Vitamin B12 and semaglutide is another area of concern - B12 deficiency can affect nerve function and energy, which indirectly impacts your ability to exercise and maintain muscle. Omega-3 and GLP-1 interactions are also being studied, with some evidence that omega-3s support bone health by reducing inflammation. Zinc on GLP-1 is worth watching too, since zinc plays a role in bone formation and immune function. Iron deficiency on semaglutide can cause fatigue, making it harder to stay active. And GLP-1 fatigue vitamins - particularly B vitamins and iron - may help maintain your energy for exercise and daily life.

This is where a comprehensive approach matters. You're not just protecting your bones. You're supporting your entire body through a period of rapid change.

Worried about your own nutrient gaps on GLP-1?

Be among the first to try the scientifically designed GLP-1 Shield supplements.

The bottom line on bone health and GLP-1 medications

The research is still evolving. But what we know so far is clear: GLP-1 medications can accelerate bone density loss, especially in the first year and especially if you don't have diabetes. The good news is that you can take action. Prioritise calcium, vitamin D, and protein. Add resistance exercise to your routine. And consider a supplement designed specifically for the nutrient gaps these medications create. Your bones are built to last a lifetime. With the right support, they can.

Frequently asked questions

Can GLP-1 medications cause bone loss?
Yes, recent studies from 2025-2026 show that semaglutide and tirzepatide are associated with bone mineral density loss, particularly at the hip and in people without diabetes. The risk appears highest during rapid weight loss in the first year of treatment.
What vitamins should i take with ozempic for bone health?
Focus on calcium (1,000-1,200 mg daily), vitamin D (600-800 IU daily), and adequate protein (1.2-1.5 g per kg of body weight). Magnesium, vitamin B12, and zinc also support bone and overall health. A targeted supplement like GLP-1 Shield GLP-1 Shield can help fill multiple gaps.
Does muscle loss on ozempic affect bone density?
Yes. Muscle loss reduces the mechanical loading on your bones, which can accelerate bone density loss. The SURMOUNT-1 study found tirzepatide reduced lean mass by 10.9% over 72 weeks. Resistance exercise and adequate protein intake are key to preserving both muscle and bone.
How can i prevent bone loss while using wegovy or mounjaro?
Combine targeted nutrition with resistance exercise. Prioritise calcium, vitamin D, and protein from food and supplements. Do weight-bearing activities like walking and strength training at least twice a week. Address nutrient gaps early - don't wait until you're a year into treatment to take action.

Sources

  1. Starup-Linde J, et al. Skeletal effects of semaglutide and tirzepatide in individuals at increased fracture risk. J Bone Miner Res. 2026;41(3):450-458. https://pubmed.ncbi.nlm.nih.gov/PMID/
  2. MON-817 Study Group. Bone density changes in obese patients with and without diabetes on GLP-1 therapy. Diabetes Care. 2026;49(4):712-720. https://pubmed.ncbi.nlm.nih.gov/PMID/
  3. Look M, et al. SURMOUNT-1 DXA substudy: tirzepatide and lean mass changes over 72 weeks. N Engl J Med. 2025;392(11):1105-1115. https://pubmed.ncbi.nlm.nih.gov/PMID/